Newsroom

TURÍN, Italia--(BUSINESS WIRE)--Reply [EXM, STAR: REY] anunció hoy la publicación de “From Code to Control: AI’s Takeover of Software Development Lifecycle” (Del código al control: la IA se apodera del ciclo de desarrollo de software), un estudio encargado por Forrester Consulting. La investigación, que relevó la opinión de 536 ejecutivos de TI en Europa y los Estados Unidos, destaca la transición progresiva de simples asistentes de programación de IA a agentes autónomos capaces de orquesta tod...

TURIJN, Italië--(BUSINESS WIRE)--Reply [EXM, STAR: REY] heeft vandaag de publicatie aangekondigd van 'From Code to Control: AI’s Takeover of Software Development Lifecycle', een onderzoek in opdracht van Forrester Consulting. Het onderzoek, waarvoor 536 IT-managers in Europa en de VS werden ondervraagd, benadrukt de geleidelijke overgang van eenvoudige AI-codeerassistenten naar autonome agents die in staat zijn de volledige softwareontwikkelingslevenscyclus (SDLC) te orkestreren. De studie onde...

LONDON--(BUSINESS WIRE)--New primary research data from Omdia reveals that media multitasking is no longer just a Gen Z habit. More than half of adults aged 45–54 now watch video clips on their mobile phones while watching television, highlighting a major shift in viewing behavior and the growing fragmentation of attention across screens. According to Omdia’s latest consumer research, 52% of US viewers aged 45–54 reported watching video clips on their phones while watching TV in November 2025,...

CAMDEN, N.J.--(BUSINESS WIRE)--The Campbell's Company (NASDAQ:CPB) today reported results for its second quarter fiscal 2026 ended February 1, 2026. Unless otherwise stated, all comparisons are to the same period of fiscal 2025. CEO Comments: "Our core Meals & Beverages portfolio delivered in-market consumption growth in the second quarter, highlighted by the Rao’s brand surpassing $1 billion in trailing twelve-month net sales. Overall results, however, fell short of our expectations due to...

DENVER--(BUSINESS WIRE)--BKV Corporation (“BKV” or the “Company”) (NYSE: BKV) today announced the pricing of its underwritten public offering of 9,692,089 shares of its common stock (the “Offering”), which includes 5,550,000 shares being offered by the Company and 4,142,089 shares being offered by Bedrock Energy Partners, LLC (the “selling stockholder”). The total estimated gross proceeds of the Offering, before deducting the underwriter’s discounts and commissions and estimated Offering fees a...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Teachers Insurance and Annuity Association of America/TIAA-CREF Investment Management, LLC/Teachers Advisors, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle compan...

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to international pharmaceutical and medical device companies seeking a streamlined path into European, including the United Kingdom and Switzerland, plus Australian, Canadian, and U.S. markets. Particularly, Veristat has helped many Chinese companies – including Hansoh Pharma and CStone Pharmaceut...

NEW YORK--(BUSINESS WIRE)--Sprinklr Announces Fourth Quarter and Full Year Fiscal 2026 Results...

MCLEAN, Va.--(BUSINESS WIRE)--Verituity announces an expansion of its verification framework with confidence-based Payment Method Verification at the point of payout....

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company’s PBGENE-HBV program. The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, tit...